800-Patient study aims to unlock secrets of autoimmune liver disease
NCT ID NCT07594990
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This French study will collect medical data and biological samples from 800 people with autoimmune liver diseases. Researchers hope to identify new markers that explain why some patients respond well to treatment while others do not. The goal is to better understand the immune mechanisms behind these diseases, which could eventually lead to more effective treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could reveal why some patients respond to treatment and others do not, pointing toward more personalized therapies for autoimmune liver diseases.
What could go wrong
This is an observational study, not a treatment trial. It will not directly test any new drug or cure, and results may take years to translate into clinical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AP-HP Beaujon
Clichy, France
Contact Email: •••••@•••••
-
AP-HP Paul Brousse
Villejuif, France
Contact Email: •••••@•••••
-
AP-HP Saint-Antoine
Paris, France
Contact Email: •••••@•••••
-
CHD Vendée
La Roche-sur-Yon, France
Contact Email: •••••@•••••
-
CHU Nantes
Nantes, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Poitiers
Poitiers, France
Contact Email: •••••@•••••
-
CHU d'Angers
Angers, France
Contact Email: •••••@•••••
-
CHU de Brest
Brest, France
Contact Email: •••••@•••••
-
CHU de Lille
Lille, France
Contact Email: •••••@•••••
-
CHU de Rennes
Rennes, France
Contact Email: •••••@•••••
-
CHU de Toulouse
Toulouse, France
Contact Email: •••••@•••••
-
CHU de Tours
Tours, France
Contact Email: •••••@•••••
-
Hospices Civils de Lyon
Lyon, France
Contact Email: •••••@•••••